Not Yet Recruiting PHASE2 INTERVENTIONAL 2-arm NCT07128576

Romiplostim N01 for the Treatment of Thrombocytopenia Associated With Radiotherapy-Combined Treatment Regimens in Patients With Solid Tumors

A Multicenter Phase II Clinical Study of Romiplostim N01 for the Treatment of Thrombocytopenia Associated With Radiotherapy-Combined Treatment Regimens in Patients With Solid Tumors

Sponsor: Zhujiang Hospital

Conditions Solid Tumors

Interventions Romiplostim N01

Updated 2 times since 2025 Last updated: Aug 28, 2025 Started: Sep 15, 2025 Primary completion: Aug 15, 2027 Completion: Dec 31, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Solid Tumors and is currently actively recruiting participants. Zhujiang Hospital leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

2 versions recorded

Oct 2025 — Present [monthly]

Not Yet Recruiting PHASE2
Sep 2025 — Oct 2025 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Zhujiang Hospital

Data source: Zhujiang Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.